Satellos Bioscience Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2025 · Filed Mar 27, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.3 · OUTSTANDING SHARE DATA
OUTSTANDING SHARE DATA
As of the date of this MD&A, the Company had the following issued and outstanding securities:
| | | |
|---|---|---|
| Security | | Number |
| Common shares | | 20,831,190 |
| Pre-Funded Warrants | | 3,450,522 |
| Stock options | | 2,194,453 |
On January 27, 2026, subsequent to the reporting period, the Company completed the Consolidation. The outstanding share data presented in this table have been retroactively adjusted to reflect the Consolidation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.